Register for our free email digests:
Division of Merck KGAA
Latest From Acadia Pharmaceuticals Inc.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
2016 witnessed a second straight year of decline in the number of new active substance launches worldwide, but trend data show that this hard measure of R&D productivity was still healthy compared with industry's performance during the first decade of the century.
Entering 2017 with freshly approved Spinraza and new CEO Michel Vounatsos, Biogen still faces challenges and uncertainty. A poll of investors highlights expectations for the company.
Sales expectations for the products of companies like Acadia, BTG, Keryx and probably Sarepta remain too high, despite the bursting of the last biotech bubble. Aggressive price increases have traditionally been one way to inch closer to those expectations but that door has closed.
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Therapeutic Areas
- Microbiological Associates
- North America
- Parent & Subsidiaries
- Merck KGAA
- Senior Management
Charles Harwood, Pres. & CEO
David Onions, PhD, CSO
David L Bellitt, VP, Global Commercial Ops., Biologics
- Contact Info
Phone: (301) 738-1000
14920 Broschart Rd.
Rockville, MD 20850-3349
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.